Bevasiranib
Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 959961-96-7
- 分子量:13345.07
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体内実験
Bevasiranib (0.5-2.0 mg/eye; intravitreal administration; single bolus dose) achieves broad ocular distribution and substantial and sustained uptake in the retina in Dutch Belted rabbits[2].
Bevasiranib (2 mg/eye; intravitreal; single bolus dose) delivers intact siRNA to multiple ocular tissues, including the retina and RPE, in male Dutch Belted rabbits, with RPE levels ranging from 423 ng to 2696 ng per eye[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (laser photocoagulation-induced CNV model)[1]
-
Dosage:70 µg; 150 µg; 350 µg
-
Administration:intravitreal injection; three doses
-
Result:Significantly inhibited the growth of the neovascular area compared to control animals for all three doses.
Reduced CNV area by greater than 50% relative to the control group.
Reduced vascular leakage as determined by fluorescein angiograms significantly in a dose-dependent manner.
-
Animal Model:Dutch-Belted rabbits (both male and female; approximately 5 months of age; body weight 1.9-2.9 kg)[2]
-
Dosage:0.5, 2.0 mg/eye
-
Administration:intravitreal; single bolus dose; 50 µl/eye, both eyes treated
-
Result:Achieved broad ocular distribution in Dutch Belted rabbits, with substantial and sustained uptake in the retina, reaching retinal drug concentrations of 370 µg-eq/g (0.5 mg/eye dose) and 683 µg-eq/g (2.0 mg/eye dose) in male rabbits, with vitreous elimination T1/2 of 30 h and 52 h, respectively.
-
Animal Model:Dutch-Belted rabbits (male; body weight 2.0-2.4 kg)[2]
-
Dosage:2 mg/eye
-
Administration:intravitreal; single bolus dose; 50 µl/eye, 5 eyes treated across 3 animals
-
Result:Detected intact Bevasiranib in aqueous fluid, vitreous fluid, iris, ciliary body, RPE, choroid and retina at 24 h after intravitreal injection; showed the highest substance levels in vitreous fluid which exceeded upper limit of quantification in 4 out of 5 tested eyes, and intact compound was absent in lens tissue for 4 out of 5 eyes. Measured low absolute mass and low percentage of administered dose for intact Bevasiranib in RPE, iris, aqueous fluid, retina and choroid tissue samples.
化学情報
-
CAS 番号 959961-96-7
-
分子量 13345.07
-
SMILES
[Bevasiranib]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Garba AO, et al. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmology and eye diseases. 2010;2:75-83. [Content Brief]
[2]. Dejneka NS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Molecular vision. 2008 May 28;14:997-1005. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Bevasiranib
- 959961-96-7
- VEGFR
- Small Interfering RNA (siRNA)
- Vascular endothelial growth factor receptor
- choroidal neovascularization
- non-human primate model
- retinal pigment epithelium-Bruch's membrane complex
- VEGF-A
- wet age-related macular degeneration
- RNA interference
- Dutch-Belted rabbits
- RNA-induced silencing complex
- TLR3
- siRNA
- Inhibitor
- inhibitor
- inhibit